Skip to main content
SpringerLink
Log in

Genetic Counseling in Hereditary Breast and Ovarian Cancer

  • Chapter
  • First Online:
Hereditary Breast and Ovarian Cancer

  • 515 Accesses

Abstract

Those with mutations in BRCA1 or BRCA2 germlines are diagnosed with hereditary breast and ovarian cancer (HBOC). BRCA1/BRCA2 genetic testing could facilitate the selection of a surgical method, early detection of related lesions, early treatment, or preventive intervention; thus, its clinical utility is high. In recent years, it has become even more important to identify patients with BRCA1/BRCA2 mutations because of the potential of chemotherapy with platinum formulations and poly ADP ribose polymerase (PARP) inhibitors. In contrast, genetic information obtained through such a test could cause unexpected confusion and mental conflict; therefore, the role of genetic counseling before and after genetic testing is significant. In this chapter, we will discuss an outline of genetic counseling associated with HBOC and important points that providers of genetic counseling need to know.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Society of Genetic Counselors’ Definition Task Force, Resta R, Biesecker BB, Bennett RL, Blum S, Hahn SE, et al. A new definition of genetic counseling: National Society of Genetic Counselors’ Task Force report. J Genet Couns. 2006;15:77–83.

    Article  Google Scholar 

  2. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17:70–87.

    Article  Google Scholar 

  3. National Institute for Health and Care Excellence. Clinical guidelines. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. https://www.nice.org.uk/guidance/CG164. Accessed 13 Oct 2020.

  4. US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer US preventive services task force recommendation statement. JAMA. 2019;322:652–65.

    Article  Google Scholar 

  5. González-Santiago S, Ramón y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, et al. SEOM clinical guidelines in hereditary breast and ovarian cancer (2019). Clin Transl Oncol. 2020;22:193–200.

    Article  Google Scholar 

  6. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24:628–37.

    Article  CAS  Google Scholar 

  7. Keung MYT, Wu Y, Vadgama JV. PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers. J Clin Med. 2019;8:435.

    Article  CAS  Google Scholar 

  8. Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of hereditary breast Cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37:453–60.

    Article  Google Scholar 

  9. Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, et al. Consensus guidelines on genetic’ testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26:3025–31.

    Article  Google Scholar 

  10. The National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Ver1. 2021. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed 13 Oct 2020.

  11. Forbes C, Fayter D, Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019;11:2321–37.

    Article  Google Scholar 

  12. Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013;22:155–63.

    Article  Google Scholar 

  13. Uhlmann WR. In: Uhlmann WR, Schuette JL, Yashar B, editors. A guide to genetic counseling. 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2009. p. 93–131.

    Google Scholar 

  14. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chronic Dis. 1985;38:289–93.

    Article  CAS  Google Scholar 

  15. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

    Article  Google Scholar 

  16. Matloff ET, Bonadies DC. In: VT DV, Lawrence TS, Rosenberg SA, editors. Cancer: principles & practice of oncology: primer of the molecular biology of cancer. Philadelphia, PA: Lippincott Williams & Wilkins; 2015. p. 405–15.

    Google Scholar 

  17. Euhus D. Genetic testing today. Ann Surg Oncol. 2014;21:3209–15.

    Article  Google Scholar 

  18. Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011;17:210–2.

    Article  Google Scholar 

  19. Nycum G, Knoppers BM, Avard D. Intra-familial obligations to communicate genetic risk information: what foundations? What forms? McGill J Law Health. 2009;3:21–48.

    Google Scholar 

  20. American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 1995;57:1233–41.

    Google Scholar 

  21. United Nations Educational, Scientific and Cultural Organization. International declaration on human genetic data. http://portal.unesco.org/en/ev.php-URL_ID=17720&URL_DO=DO_TOPIC&URL_SECTION=201.html. Accessed 13 Oct 2020.

  22. The Genetic Information Nondiscrimination Act of 2008 (H.R.493). https://www.congress.gov/bill/110th-congress/house-bill/493. Accessed 13 Oct 2020.

  23. Schlich-Bakker KJ, Kroode HFJ, Wárlám-Rodenhuis CC, Bout J, Ausems MGEM. Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer. Genet Med. 2007;9:766–77.

    Article  Google Scholar 

  24. Eijzenga W, Hahn DEE, Aaronson NK, Kluijt I, Bleiker EMA. Specific psychosocial issues of individuals undergoing genetic counseling for cancer - a literature review. J Genet Couns. 2014;23:133–46.

    Article  Google Scholar 

  25. Lewis KM. Identifying hereditary cancer: genetic counseling and cancer risk assessment. Curr Probl Cancer. 2014;38:216–25.

    Article  Google Scholar 

  26. Chan JL, Johnson LN, Sammel MD, DiGiovanni L, Voong C, Domchek SM, Gracia CR. Reproductive decision-making in women with BRCA1/2 mutations. J Genet Couns. 2017;26:594–603.

    Article  Google Scholar 

  27. Baty BJ. In: Uhlmann WR, Schuette JL, Yashar B, editors. A guide to genetic counseling, second edition. Hoboken, NJ: Wiley-Blackwell; 2009. p. 207–50.

    Google Scholar 

  28. Henneman L, Marteau TM, Timmermans DRM. Clinical geneticists’ and genetic counselors’ views on the communication of genetic risks: a qualitative study. Patient Educ Couns. 2008;73:42–9.

    Article  Google Scholar 

  29. Timmermans D. The roles of experience and domain of expertise in using numerical and verbal probability terms in medical decisions. Med Decis Mak. 1994;14:146–56.

    Article  CAS  Google Scholar 

  30. Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Mak. 2001;21:37–44.

    Article  CAS  Google Scholar 

  31. Lautenbach DM, Christensen KD, Sparks JA, Green RC. Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet. 2013;14:491–513.

    Article  CAS  Google Scholar 

  32. Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C, Balshem A. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst. 1995;87:286–92.

    Article  CAS  Google Scholar 

  33. Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J, et al. Factors influencing Cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract. 2011;9:2.

    Article  Google Scholar 

  34. Foster C, Evans DGR, Eeles R, Eccles D, Ashley S, Brooks L, et al. Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer. 2002;86:1209–16.

    Article  CAS  Google Scholar 

  35. Association for Molecular Pathology v. Myriad Genetics. 133 U.S. Supreme Court 2107 C.F.R.; 2013.

    Google Scholar 

  36. Hooker GW, Clemens KR, Quillin J, Postula KJV, Summerour P, Nagy R, et al. Cancer genetic counseling and testing in an era of rapid change. J Genet Couns. 2017;26:1244–53.

    Article  Google Scholar 

  37. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32:2001–9.

    Article  CAS  Google Scholar 

  38. Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst. 2018;110:714–25.

    Article  Google Scholar 

  39. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25–33.

    Article  CAS  Google Scholar 

  40. Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR, Younesi L. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol. 2019;12:38.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetic Counseling, Showa University Graduate School of Health Sciences, Tokyo, Japan

    Mayuko Inuzuka

Authors
  1. Mayuko Inuzuka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mayuko Inuzuka .

Editor information

Editors and Affiliations

  1. Department of Breast Surgical Oncology, Showa University, School of Medicine, Tokyo, Japan

    Seigo Nakamura

  2. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan

    Daisuke Aoki

  3. Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

    Yoshio Miki

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Inuzuka, M. (2021). Genetic Counseling in Hereditary Breast and Ovarian Cancer. In: Nakamura, S., Aoki, D., Miki, Y. (eds) Hereditary Breast and Ovarian Cancer . Springer, Singapore. https://doi.org/10.1007/978-981-16-4521-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-4521-1_5

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-4520-4

  • Online ISBN: 978-981-16-4521-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation